$DRI

DARDEN RESTAURANTS INC

4
1
2

No SEC Form 4 filings for $DRI in the last 30 days.

See all $DRI insider activity →

Starbucks initiated, Expedia downgraded: Wall Street's top analyst calls

Analysts made several rating changes: Wolfe upgraded Paychex (PAYX) citing stable employment trends. UBS upgraded Union Pacific (UNP) to Buy with a $339 price target, expecting strong 2027 volume growth. Needham upgraded Rocket Pharmaceuticals (RCKT) to Buy with a $9 target after FDA reaffirmed study design. JPMorgan upgraded Credicorp (BAP) to Overweight with a $482 target, seeing strong EPS growth. Morgan Stanley downgraded Expedia (EXPE) to Underweight with a $235 target, citing weaker assets

DRI sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 7 news stories mentioning DRI (DARDEN RESTAURANTS INC). Coverage has skewed bullish: 4 bullish, 1 neutral, and 2 bearish.

Recent DRI coverage spans financial news, earnings and corporate actions.

What's driving DRI

AlphAI scores every news story that mentions DRI with an AI model for sentiment and relevance, and aggregates insider trades from DARDEN RESTAURANTS INC's SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $DRI

Score

Starbucks initiated, Expedia downgraded: Wall Street's top analyst calls

Analysts made several rating changes: Wolfe upgraded Paychex (PAYX) citing stable employment trends. UBS upgraded Union Pacific (UNP) to Buy with a $339 price target, expecting strong 2027 volume growth. Needham upgraded Rocket Pharmaceuticals (RCKT) to Buy with a $9 target after FDA reaffirmed study design. JPMorgan upgraded Credicorp (BAP) to Overweight with a $482 target, seeing strong EPS growth. Morgan Stanley downgraded Expedia (EXPE) to Underweight with a $235 target, citing weaker assets

$DRIMed

DRI Maintained by Oppenheimer -- Price Target Raised to $245

Oppenheimer maintained its 'Outperform' rating on Darden Restaurants (DRI) and raised its price target to $245 from $235, citing confidence in the company's growth prospects. DRI's GF Value™ is $211.60, indicating a slight premium. The stock has a GF Score™ of 84/100, with strong profitability and momentum but lower financial strength. Insider selling has been significant, with $15.56M in sales over the last three months.

$DRIMed

DRI Maintained by Morgan Stanley -- Price Target Raised to $255

Morgan Stanley maintained an Overweight rating on Darden Restaurants (DRI) and raised its price target to $255 from $236, citing growth potential. DRI is currently trading at $214.43, slightly above its GF Value™ of $211.57, indicating a 1.4% overvaluation. The company has a GF Score™ of 85, reflecting strong financial health and profitability.

$DRIMed

DRI Maintained by Citigroup -- Price Target Raised to $248

Citigroup maintained a 'Buy' rating on Darden Restaurants (DRI), raising its price target to $248 from $245. The company's GF Value™ is $211.48, indicating a 1.1% undervaluation. DRI has a GF Score™ of 85/100, with strong profitability and valuation metrics. Insider activity shows significant selling, with $15.56M in sales over the last three months.

Olive Garden owner targets Jamaica for expansion

Darden Restaurants, owner of Olive Garden and Ruth’s Chris Steak House, has franchise agreements in Jamaica, according to its latest annual filing. The company operates 2,373 restaurants globally, with plans to expand in the Caribbean. Darden reported a 9.4% increase in total sales to $13.2 billion in fiscal 2026, driven by strong performance from its top brands: Olive Garden, LongHorn Steakhouse, and Yard House. The company also announced plans to wind down its Bahama Breeze brand.

Related tickers